Frazier-Backed Mavupharma Scores $20M to Fund STING Program Post author:Sam Post published:November 28, 2017 Post category:BioPharma The Series A funding will be used primarily to advance Mavu’s lead drug candidates into the clinic. Source: BioSpace You Might Also Like <b>ZEISS</b> Unveils Ultra-Widefield Fundus Imaging Technology In U.S. September 14, 2017 Bay Area's IMPAX Labs Surges on Merger Buzz September 21, 2017 Two Drugmakers Compete for Sanofi's $2.4B Generics Biz February 5, 2018